Clinical trial · Observational
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Based on hmC-Seal Technology
NCT03493763CI-TRIAL-00032444unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, investigators aim to find out how plasma 5hmC level changes in hepatocellular carcinoma patients after liver resection, and determine whether 5hmC can be used as a biomarker for HCC recurrence monitoring.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5hmC profile in plasma cell-free DNA after liver resection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- serum AFP negative HCC patients
- description
- 1. Patients who received liver resection within 3 months; 2. Hepatocellular carcinoma confirmed pathologically; 3. Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy.
- interventionNames
- Diagnostic Test: 5hmC profile in plasma cell-free DNA after liver resection
Primary outcomes (1)
- measure
- Time of hepatocellular carcinoma recurrence
- timeFrame
- 2 years
- description
- Time from the day of liver resection to the day of clinical diagnosis of recurrence
Secondary outcomes (3)
- measure
- 5hmC level in recurrence-related cfDNA after liver resection
- timeFrame
- 2 years or until tumor recurrence
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who received liver resection within 3 months; 2. Hepatocellular carcinoma confirmed pathologically; 3. Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy. Exclusion Criteria: 1. Patients with macroscopic tumor remnants; 2. Patients with other diseases which may affect the observation mentioned here; 3. Patients with medical history of other malignant tumors; 4. Pregnant or nursing women.
References
Publications (0)
Data not yet available
No reference posted for this study.